Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication

DOI record: { "DOI": "10.1016/j.bbadis.2021.166294", "ISSN": [ "0925-4439" ], "URL": "http://dx.doi.org/10.1016/j.bbadis.2021.166294", "alternative-id": [ "S0925443921002271" ], "article-number": "166294", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication" }, { "label": "Journal Title", "name": "journaltitle", "value": "Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.bbadis.2021.166294" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2021 Elsevier B.V." } ], "author": [ { "affiliation": [], "family": "Low", "given": "Zheng Yao", "sequence": "first" }, { "affiliation": [], "family": "Yip", "given": "Ashley Jia Wen", "sequence": "additional" }, { "affiliation": [], "family": "Lal", "given": "Sunil K.", "sequence": "additional" } ], "container-title": "Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease", "container-title-short": "Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease", "content-domain": { "crossmark-restriction": true, "domain": [ "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2021, 10, 22 ] ], "date-time": "2021-10-22T01:41:47Z", "timestamp": 1634866907000 }, "deposited": { "date-parts": [ [ 2023, 3, 6 ] ], "date-time": "2023-03-06T15:26:35Z", "timestamp": 1678116395000 }, "indexed": { "date-parts": [ [ 2024, 5, 13 ] ], "date-time": "2024-05-13T21:14:52Z", "timestamp": 1715634892014 }, "is-referenced-by-count": 30, "issue": "2", "issued": { "date-parts": [ [ 2022, 2 ] ] }, "journal-issue": { "issue": "2", "published-print": { "date-parts": [ [ 2022, 2 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 2, 1 ] ], "date-time": "2022-02-01T00:00:00Z", "timestamp": 1643673600000 } }, { "URL": "http://www.elsevier.com/open-access/userlicense/1.0/", "content-version": "vor", "delay-in-days": 365, "start": { "date-parts": [ [ 2023, 2, 1 ] ], "date-time": "2023-02-01T00:00:00Z", "timestamp": 1675209600000 } }, { "URL": "https://doi.org/10.15223/policy-017", "content-version": "stm-asf", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 2, 1 ] ], "date-time": "2022-02-01T00:00:00Z", "timestamp": 1643673600000 } }, { "URL": "https://doi.org/10.15223/policy-037", "content-version": "stm-asf", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 2, 1 ] ], "date-time": "2022-02-01T00:00:00Z", "timestamp": 1643673600000 } }, { "URL": "https://doi.org/10.15223/policy-012", "content-version": "stm-asf", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 2, 1 ] ], "date-time": "2022-02-01T00:00:00Z", "timestamp": 1643673600000 } }, { "URL": "https://doi.org/10.15223/policy-029", "content-version": "stm-asf", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 2, 1 ] ], "date-time": "2022-02-01T00:00:00Z", "timestamp": 1643673600000 } }, { "URL": "https://doi.org/10.15223/policy-004", "content-version": "stm-asf", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 2, 1 ] ], "date-time": "2022-02-01T00:00:00Z", "timestamp": 1643673600000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0925443921002271?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0925443921002271?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "166294", "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 2 ] ] }, "published-print": { "date-parts": [ [ 2022, 2 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1038/s41591-020-0820-9", "article-title": "The proximal origin of SARS-CoV-2", "author": "Andersen", "doi-asserted-by": "crossref", "first-page": "450", "journal-title": "Nat. Med.", "key": "10.1016/j.bbadis.2021.166294_bb0010", "volume": "26", "year": "2020" }, { "DOI": "10.3389/fphar.2020.00836", "article-title": "Molecular insights into SARS COV-2 interaction with cardiovascular disease: role of RAAS and MAPK signaling", "author": "Wehbe", "doi-asserted-by": "crossref", "journal-title": "Front. Pharmacol.", "key": "10.1016/j.bbadis.2021.166294_bb0015", "volume": "11", "year": "2020" }, { "DOI": "10.3390/v12091058", "article-title": "Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak", "author": "Low", "doi-asserted-by": "crossref", "first-page": "1058", "journal-title": "Viruses", "key": "10.1016/j.bbadis.2021.166294_bb0020", "volume": "12", "year": "2020" }, { "article-title": "COVID-19: a review on the novel coronavirus disease evolution, transmission, detectionControl and Prevention", "author": "Sharma", "first-page": "202", "key": "10.1016/j.bbadis.2021.166294_bb0025", "volume": "13", "year": "2021" }, { "DOI": "10.1016/j.jmgm.2020.107762", "article-title": "Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach", "author": "Bello", "doi-asserted-by": "crossref", "journal-title": "J. Mol. Graph. Model.", "key": "10.1016/j.bbadis.2021.166294_bb0030", "volume": "101", "year": "2020" }, { "DOI": "10.1007/s00894-020-04600-4", "article-title": "Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA", "author": "Bello", "doi-asserted-by": "crossref", "journal-title": "J. Mol. Model.", "key": "10.1016/j.bbadis.2021.166294_bb0035", "volume": "26", "year": "2020" }, { "DOI": "10.3390/ph14050454", "article-title": "Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection", "author": "Zanella", "doi-asserted-by": "crossref", "first-page": "454", "journal-title": "Pharmaceuticals", "key": "10.1016/j.bbadis.2021.166294_bb0040", "volume": "14", "year": "2021" }, { "DOI": "10.1128/AAC.00819-20", "article-title": "Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs", "author": "Jeon", "doi-asserted-by": "crossref", "journal-title": "Antimicrob. Agents Chemother.", "key": "10.1016/j.bbadis.2021.166294_bb0045", "volume": "64", "year": "2020" }, { "DOI": "10.1016/j.pt.2017.02.004", "article-title": "Ivermectin – old drug, new Tricks?", "author": "Laing", "doi-asserted-by": "crossref", "first-page": "463", "journal-title": "Trends Parasitol.", "key": "10.1016/j.bbadis.2021.166294_bb0050", "volume": "33", "year": "2017" }, { "DOI": "10.1016/j.ijantimicag.2007.08.023", "article-title": "Ivermectin: 25 years and still going strong", "author": "Õmura", "doi-asserted-by": "crossref", "first-page": "91", "journal-title": "Int. J. Antimicrob. Agents", "key": "10.1016/j.bbadis.2021.166294_bb0055", "volume": "31", "year": "2008" }, { "DOI": "10.1126/science.6308762", "article-title": "Ivermectin: a potent new antiparasitic agent", "author": "Campbell", "doi-asserted-by": "crossref", "first-page": "823", "journal-title": "Science", "key": "10.1016/j.bbadis.2021.166294_bb0060", "volume": "221", "year": "1983" }, { "DOI": "10.1038/nrmicro1048", "article-title": "The life and times of ivermectin — a success story", "author": "Õmura", "doi-asserted-by": "crossref", "first-page": "984", "journal-title": "Nat. Rev. Microbiol.", "key": "10.1016/j.bbadis.2021.166294_bb0065", "volume": "2", "year": "2004" }, { "DOI": "10.1016/j.ijantimicag.2019.05.003", "article-title": "Ivermectin: from theory to clinical application", "author": "Ashour", "doi-asserted-by": "crossref", "first-page": "134", "journal-title": "Int. J. Antimicrob. Agents", "key": "10.1016/j.bbadis.2021.166294_bb0070", "volume": "54", "year": "2019" }, { "DOI": "10.1111/j.1365-3156.2004.01211.x", "article-title": "Review: the delivery of ivermectin (MectizanR)", "author": "Burnham", "doi-asserted-by": "crossref", "first-page": "A26", "journal-title": "Trop. Med. Int. Health", "key": "10.1016/j.bbadis.2021.166294_bb0075", "volume": "9", "year": "2004" }, { "DOI": "10.3390/antibiotics10040381", "article-title": "Repurposing avermectins and milbemycins against mycobacteroides abscessus and other nontuberculous mycobacteria", "author": "Muñoz-Muñoz", "doi-asserted-by": "crossref", "first-page": "381", "journal-title": "Antibiotics", "key": "10.1016/j.bbadis.2021.166294_bb0080", "volume": "10", "year": "2021" }, { "DOI": "10.1016/j.phrs.2020.105207", "article-title": "Ivermectin, a potential anticancer drug derived from an antiparasitic drug", "author": "Tang", "doi-asserted-by": "crossref", "journal-title": "Pharmacol. Res.", "key": "10.1016/j.bbadis.2021.166294_bb0085", "volume": "163", "year": "2021" }, { "DOI": "10.1093/brain/awv167", "article-title": "DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis", "author": "Yin", "doi-asserted-by": "crossref", "first-page": "2553", "journal-title": "Brain", "key": "10.1016/j.bbadis.2021.166294_bb0090", "volume": "138", "year": "2015" }, { "DOI": "10.1038/srep17288", "article-title": "Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease", "author": "Jin", "doi-asserted-by": "crossref", "journal-title": "Sci. Rep.", "key": "10.1016/j.bbadis.2021.166294_bb0095", "volume": "5", "year": "2015" }, { "DOI": "10.1093/jac/dks147", "article-title": "Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug", "author": "Mastrangelo", "doi-asserted-by": "crossref", "first-page": "1884", "journal-title": "J. Antimicrob. Chemother.", "key": "10.1016/j.bbadis.2021.166294_bb0100", "volume": "67", "year": "2012" }, { "DOI": "10.1042/BJ20120150", "article-title": "Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus", "author": "Wagstaff", "doi-asserted-by": "crossref", "first-page": "851", "journal-title": "Biochem. J.", "key": "10.1016/j.bbadis.2021.166294_bb0105", "volume": "443", "year": "2012" }, { "DOI": "10.1016/j.antiviral.2020.104787", "article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro", "author": "Caly", "doi-asserted-by": "crossref", "journal-title": "Antivir. Res.", "key": "10.1016/j.bbadis.2021.166294_bb0110", "volume": "178", "year": "2020" }, { "DOI": "10.3389/fimmu.2021.663586", "article-title": "Repurposing ivermectin for COVID-19: molecular aspects and therapeutic possibilities", "author": "Wehbe", "doi-asserted-by": "crossref", "journal-title": "Front. Immunol.", "key": "10.1016/j.bbadis.2021.166294_bb0115", "volume": "12", "year": "2021" }, { "DOI": "10.1080/00480169.1981.34836", "article-title": "An introduction to the avermectins", "author": "Campbell", "doi-asserted-by": "crossref", "first-page": "174", "journal-title": "N. Z. Vet. J.", "key": "10.1016/j.bbadis.2021.166294_bb0120", "volume": "29", "year": "1981" }, { "DOI": "10.1007/s43440-020-00195-y", "article-title": "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes", "author": "Kaur", "doi-asserted-by": "crossref", "first-page": "736", "journal-title": "Pharmacol. Rep.", "key": "10.1016/j.bbadis.2021.166294_bb0125", "volume": "73", "year": "2021" }, { "DOI": "10.3390/cells9092100", "article-title": "Ivermectin as a broad-Spectrum host-directed antiviral: the real deal?", "author": "Jans", "doi-asserted-by": "crossref", "first-page": "2100", "journal-title": "Cells", "key": "10.1016/j.bbadis.2021.166294_bb0130", "volume": "9", "year": "2020" }, { "DOI": "10.4269/ajtmh.20-0271", "article-title": "Ivermectin and COVID-19: keeping rigor in times of urgency", "author": "Chaccour", "doi-asserted-by": "crossref", "first-page": "1156", "journal-title": "Am. J. Trop. Med. Hyg.", "key": "10.1016/j.bbadis.2021.166294_bb0135", "volume": "102", "year": "2020" }, { "DOI": "10.3389/fphar.2020.01196", "article-title": "COVID-19 therapeutic options under investigation", "author": "Kaddoura", "doi-asserted-by": "crossref", "journal-title": "Front. Pharmacol.", "key": "10.1016/j.bbadis.2021.166294_bb0140", "volume": "11", "year": "2020" }, { "DOI": "10.1128/JVI.01012-07", "article-title": "Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/golgimembrane", "author": "Frieman", "doi-asserted-by": "crossref", "first-page": "9812", "journal-title": "J. Virol.", "key": "10.1016/j.bbadis.2021.166294_bb0145", "volume": "81", "year": "2007" }, { "DOI": "10.3389/fmicb.2015.00553", "article-title": "Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses", "author": "Wulan", "doi-asserted-by": "crossref", "journal-title": "Front. Microbiol.", "key": "10.1016/j.bbadis.2021.166294_bb0150", "volume": "6", "year": "2015" }, { "DOI": "10.1016/j.chom.2016.07.004", "article-title": "A screen of FDA-approved drugs for inhibitors of zika virus infection", "author": "Barrows", "doi-asserted-by": "crossref", "first-page": "259", "journal-title": "Cell Host Microbe", "key": "10.1016/j.bbadis.2021.166294_bb0155", "volume": "20", "year": "2016" }, { "DOI": "10.1056/NEJMra1602113", "article-title": "Zika virus", "author": "Petersen", "doi-asserted-by": "crossref", "first-page": "1552", "journal-title": "N. Engl. J. Med.", "key": "10.1016/j.bbadis.2021.166294_bb0160", "volume": "374", "year": "2016" }, { "DOI": "10.1016/j.virol.2019.10.010", "article-title": "Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication", "author": "Ji", "doi-asserted-by": "crossref", "first-page": "124", "journal-title": "Virology", "key": "10.1016/j.bbadis.2021.166294_bb0170", "volume": "541", "year": "2020" }, { "DOI": "10.1128/CMR.00045-12", "article-title": "West Nile virus: biology, transmission, and human infection", "author": "Colpitts", "doi-asserted-by": "crossref", "first-page": "635", "journal-title": "Clin. Microbiol. Rev.", "key": "10.1016/j.bbadis.2021.166294_bb0175", "volume": "25", "year": "2012" }, { "DOI": "10.1093/jac/dks147", "article-title": "Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug", "author": "Mastrangelo", "doi-asserted-by": "crossref", "first-page": "1884", "journal-title": "J. Antimicrob. Chemother.", "key": "10.1016/j.bbadis.2021.166294_bb0180", "volume": "67", "year": "2012" }, { "DOI": "10.1016/j.cell.2009.01.029", "article-title": "The influenza virus enigma", "author": "Salomon", "doi-asserted-by": "crossref", "first-page": "402", "journal-title": "Cell", "key": "10.1016/j.bbadis.2021.166294_bb0185", "volume": "136", "year": "2009" }, { "article-title": "Influenza a viruses escape from MxA restriction at the expense of efficient nuclear vRNP import", "author": "Götz", "journal-title": "Sci. Rep.", "key": "10.1016/j.bbadis.2021.166294_bb0190", "volume": "6", "year": "2016" }, { "DOI": "10.1128/JVI.02220-13", "article-title": "The human interferon-induced MxA protein inhibits early stages of influenza a virus infection by retaining the incoming viral genome in the cytoplasm", "author": "Xiao", "doi-asserted-by": "crossref", "first-page": "13053", "journal-title": "J. Virol.", "key": "10.1016/j.bbadis.2021.166294_bb0195", "volume": "87", "year": "2013" }, { "DOI": "10.1128/JVI.00712-11", "article-title": "The viral nucleoprotein determines mx sensitivity of influenza a viruses", "author": "Zimmermann", "doi-asserted-by": "crossref", "first-page": "8133", "journal-title": "J. Virol.", "key": "10.1016/j.bbadis.2021.166294_bb0200", "volume": "85", "year": "2011" }, { "DOI": "10.3389/fimmu.2018.01547", "article-title": "Advancements in host-based interventions for influenza treatment", "author": "Yip", "doi-asserted-by": "crossref", "journal-title": "Front. Immunol.", "key": "10.1016/j.bbadis.2021.166294_bb0205", "volume": "9", "year": "2018" }, { "DOI": "10.1021/cb600131q", "article-title": "Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses", "author": "Smith", "doi-asserted-by": "crossref", "first-page": "217", "journal-title": "ACS Chem. Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0210", "volume": "1", "year": "2006" }, { "DOI": "10.1016/j.antiviral.2020.104760", "article-title": "The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer", "author": "Yang", "doi-asserted-by": "crossref", "journal-title": "Antivir. Res.", "key": "10.1016/j.bbadis.2021.166294_bb0215", "volume": "177", "year": "2020" }, { "DOI": "10.1038/s41586-020-2012-7", "article-title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "270", "journal-title": "Nature", "key": "10.1016/j.bbadis.2021.166294_bb0220", "volume": "579", "year": "2020" }, { "DOI": "10.1016/j.jare.2020.03.005", "article-title": "COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses", "author": "Shereen", "doi-asserted-by": "crossref", "first-page": "91", "journal-title": "J. Adv. Res.", "key": "10.1016/j.bbadis.2021.166294_bb0225", "volume": "24", "year": "2020" }, { "DOI": "10.1016/j.bbadis.2020.165878", "article-title": "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach", "author": "Naqvi", "doi-asserted-by": "crossref", "journal-title": "Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.", "key": "10.1016/j.bbadis.2021.166294_bb0230", "volume": "1866", "year": "2020" }, { "article-title": "Coronaviruses: an overview of their replication and pathogenesis", "author": "Fehr", "first-page": "1", "journal-title": "Coronaviruses", "key": "10.1016/j.bbadis.2021.166294_bb0235", "year": "2015" }, { "DOI": "10.1128/JVI.00645-06", "article-title": "Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy", "author": "Neuman", "doi-asserted-by": "crossref", "first-page": "7918", "journal-title": "J. Virol.", "key": "10.1016/j.bbadis.2021.166294_bb0240", "volume": "80", "year": "2006" }, { "article-title": "Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin", "author": "Sen Gupta", "first-page": "1", "journal-title": "J. Biomol. Struct. Dyn.", "key": "10.1016/j.bbadis.2021.166294_bb0245", "year": "2020" }, { "DOI": "10.1128/JVI.01012-07", "article-title": "Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic Reticulum/Golgi membrane", "author": "Frieman", "doi-asserted-by": "crossref", "first-page": "9812", "journal-title": "J. Virol.", "key": "10.1016/j.bbadis.2021.166294_bb0250", "volume": "81", "year": "2007" }, { "DOI": "10.1016/j.ejmech.2021.113201", "article-title": "RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic", "author": "Tian", "doi-asserted-by": "crossref", "journal-title": "Eur. J. Med. Chem.", "key": "10.1016/j.bbadis.2021.166294_bb0255", "volume": "213", "year": "2021" }, { "article-title": "The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2", "author": "Saha", "first-page": "1", "journal-title": "Struct. Chem.", "key": "10.1016/j.bbadis.2021.166294_bb0260", "year": "2021" }, { "DOI": "10.1038/s42003-020-01577-x", "article-title": "Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents", "author": "Mody", "doi-asserted-by": "crossref", "journal-title": "Commun. Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0265", "volume": "4", "year": "2021" }, { "DOI": "10.1016/j.ceb.2019.01.001", "article-title": "Inhibitors of nuclear transport", "author": "Jans", "doi-asserted-by": "crossref", "first-page": "50", "journal-title": "Curr. Opin. Cell Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0270", "volume": "58", "year": "2019" }, { "DOI": "10.1016/j.antiviral.2012.06.008", "article-title": "Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?", "author": "Caly", "doi-asserted-by": "crossref", "first-page": "202", "journal-title": "Antivir. Res.", "key": "10.1016/j.bbadis.2021.166294_bb0275", "volume": "95", "year": "2012" }, { "DOI": "10.3390/cells8030281", "article-title": "Novel flavivirus antiviral that targets the host nuclear transport importin α/β1 heterodimer", "author": "Yang", "doi-asserted-by": "crossref", "first-page": "281", "journal-title": "Cells", "key": "10.1016/j.bbadis.2021.166294_bb0280", "volume": "8", "year": "2019" }, { "key": "10.1016/j.bbadis.2021.166294_bb0285", "unstructured": "Waheed Shouman . Prophylactic Ivermectin in COVID-19 Contacts - Study Results - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT04422561 (Accessed Jun 10, 2021)." }, { "article-title": "Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies", "author": "Hariyanto", "journal-title": "Rev. Med. Virol.", "key": "10.1016/j.bbadis.2021.166294_bb0290", "year": "2021" }, { "author": "Swargiary", "key": "10.1016/j.bbadis.2021.166294_bb0295", "series-title": "Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies", "year": "2020" }, { "DOI": "10.1038/s41418-020-00633-7", "article-title": "An aberrant STAT pathway is central to COVID-19", "author": "Matsuyama", "doi-asserted-by": "crossref", "first-page": "3209", "journal-title": "Cell Death Differ.", "key": "10.1016/j.bbadis.2021.166294_bb0300", "volume": "27", "year": "2020" }, { "DOI": "10.1016/j.chom.2020.05.008", "article-title": "Type I and type III interferons – induction, signaling, evasion, and application to combat COVID-19", "author": "Park", "doi-asserted-by": "crossref", "first-page": "870", "journal-title": "Cell Host Microbe", "key": "10.1016/j.bbadis.2021.166294_bb0305", "volume": "27", "year": "2020" }, { "DOI": "10.1074/jbc.M116.745729", "article-title": "Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-α1 degradation", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "10262", "journal-title": "J. Biol. Chem.", "key": "10.1016/j.bbadis.2021.166294_bb0310", "volume": "292", "year": "2017" }, { "DOI": "10.3390/ijms20194870", "article-title": "STAT3 regulates the type I IFN-mediated antiviral response by interfering with the nuclear entry of STAT1", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "4870", "journal-title": "Int. J. Mol. Sci.", "key": "10.1016/j.bbadis.2021.166294_bb0315", "volume": "20", "year": "2019" }, { "DOI": "10.1165/rcmb.2012-0100TR", "article-title": "Human epidermal growth factor receptor signaling in acute lung injury", "author": "Finigan", "doi-asserted-by": "crossref", "first-page": "395", "journal-title": "Am. J. Respir. Cell Mol. Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0320", "volume": "47", "year": "2012" }, { "DOI": "10.1016/j.bbrc.2016.06.065", "article-title": "Plasminogen activator inhibitor-1 stimulates macrophage activation through toll-like Receptor-4", "author": "Gupta", "doi-asserted-by": "crossref", "first-page": "503", "journal-title": "Biochem. Biophys. Res. Commun.", "key": "10.1016/j.bbadis.2021.166294_bb0325", "volume": "477", "year": "2016" }, { "DOI": "10.1165/rcmb.2008-0003ED", "article-title": "What the lung has taught us about latent TGF-β activation", "author": "Aluwihare", "doi-asserted-by": "crossref", "first-page": "499", "journal-title": "Am. J. Respir. Cell Mol. Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0330", "volume": "39", "year": "2008" }, { "DOI": "10.4049/jimmunol.1402513", "article-title": "The acute respiratory distress syndrome: from mechanism to translation", "author": "Han", "doi-asserted-by": "crossref", "first-page": "855", "journal-title": "J. Immunol.", "key": "10.1016/j.bbadis.2021.166294_bb0335", "volume": "194", "year": "2015" }, { "DOI": "10.1158/0008-5472.CAN-15-2887", "article-title": "Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt Axis in breast cancer", "author": "Dou", "doi-asserted-by": "crossref", "first-page": "4457", "journal-title": "Cancer Res.", "key": "10.1016/j.bbadis.2021.166294_bb0340", "volume": "76", "year": "2016" }, { "DOI": "10.3390/ijms22041737", "article-title": "Understanding viral infection mechanisms and patient symptoms for the development of COVID-19 therapeutics", "author": "Choi", "doi-asserted-by": "crossref", "first-page": "1737", "journal-title": "Int. J. Mol. Sci.", "key": "10.1016/j.bbadis.2021.166294_bb0345", "volume": "22", "year": "2021" }, { "DOI": "10.1038/s41423-020-0458-z", "article-title": "Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies", "author": "Yi", "doi-asserted-by": "crossref", "first-page": "621", "journal-title": "Cell. Mol. Immunol.", "key": "10.1016/j.bbadis.2021.166294_bb0350", "volume": "17", "year": "2020" }, { "DOI": "10.1016/j.gene.2020.145325", "article-title": "The potential involvement of JAK-STAT signalling pathway in the COVID-19 infection assisted by ACE2", "author": "Luo", "doi-asserted-by": "crossref", "journal-title": "Gene", "key": "10.1016/j.bbadis.2021.166294_bb0355", "volume": "768", "year": "2021" }, { "author": "Hennighausen", "key": "10.1016/j.bbadis.2021.166294_bb0360", "series-title": "Activation of the SARS-CoV-2 receptorAce2by cytokines through pan JAK-STAT enhancers", "year": "2020" }, { "DOI": "10.2217/fvl-2020-0342", "article-title": "Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in-silico approach", "author": "Choudhury", "doi-asserted-by": "crossref", "first-page": "277", "journal-title": "Futur. Virol.", "key": "10.1016/j.bbadis.2021.166294_bb0365", "volume": "16", "year": "2021" }, { "DOI": "10.21873/invivo.12134", "article-title": "Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2", "author": "Lehrer", "doi-asserted-by": "crossref", "first-page": "3023", "journal-title": "In Vivo", "key": "10.1016/j.bbadis.2021.166294_bb0370", "volume": "34", "year": "2020" }, { "article-title": "Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets", "author": "Bello", "first-page": "1", "journal-title": "J. Biomol. Struct. Dyn.", "key": "10.1016/j.bbadis.2021.166294_bb0375", "year": "2021" }, { "DOI": "10.1038/s41598-021-88630-9", "article-title": "The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors", "author": "Silvestrini", "doi-asserted-by": "crossref", "journal-title": "Sci. Rep.", "key": "10.1016/j.bbadis.2021.166294_bb0380", "volume": "11", "year": "2021" }, { "DOI": "10.1016/j.jmgm.2020.107762", "article-title": "Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach", "author": "Bello", "doi-asserted-by": "crossref", "journal-title": "J. Mol. Graph. Model.", "key": "10.1016/j.bbadis.2021.166294_bb0385", "volume": "101", "year": "2020" }, { "DOI": "10.1126/science.abb3405", "article-title": "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors", "author": "Zhang", "doi-asserted-by": "crossref", "first-page": "409", "journal-title": "Science", "key": "10.1016/j.bbadis.2021.166294_bb0390", "volume": "368", "year": "2020" }, { "DOI": "10.1038/s41586-020-2223-y", "article-title": "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors", "author": "Jin", "doi-asserted-by": "crossref", "first-page": "289", "journal-title": "Nature", "key": "10.1016/j.bbadis.2021.166294_bb0395", "volume": "582", "year": "2020" }, { "DOI": "10.1107/S2053230X20011814", "article-title": "Room-temperature neutron and X-ray data collection of 3CL mprofrom SARS-CoV-2", "author": "Kneller", "doi-asserted-by": "crossref", "first-page": "483", "journal-title": "Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.", "key": "10.1016/j.bbadis.2021.166294_bb0400", "volume": "76", "year": "2020" }, { "article-title": "Design of wide-spectrum inhibitors targeting coronavirus main proteases", "author": "Yang", "journal-title": "PLoS Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0405", "volume": "3", "year": "2005" }, { "DOI": "10.1126/science.abb4489", "article-title": "Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease", "author": "Dai", "doi-asserted-by": "crossref", "first-page": "1331", "journal-title": "Science", "key": "10.1016/j.bbadis.2021.166294_bb0410", "volume": "368", "year": "2020" }, { "DOI": "10.1016/j.jtbi.2008.07.030", "article-title": "Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors", "author": "Nukoolkarn", "doi-asserted-by": "crossref", "first-page": "861", "journal-title": "J. Theor. Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0415", "volume": "254", "year": "2008" }, { "DOI": "10.1016/j.antiviral.2020.104786", "article-title": "Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro", "author": "Choy", "doi-asserted-by": "crossref", "journal-title": "Antivir. Res.", "key": "10.1016/j.bbadis.2021.166294_bb0420", "volume": "178", "year": "2020" }, { "DOI": "10.1056/NEJMoa2001282", "article-title": "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", "author": "Cao", "doi-asserted-by": "crossref", "first-page": "1787", "journal-title": "N. Engl. J. Med.", "key": "10.1016/j.bbadis.2021.166294_bb0425", "volume": "382", "year": "2020" }, { "DOI": "10.3389/fmolb.2020.616341", "article-title": "Recent Progress in the drug development targeting SARS-CoV-2 Main protease as treatment for COVID-19", "author": "Cui", "doi-asserted-by": "crossref", "journal-title": "Front. Mol. Biosci.", "key": "10.1016/j.bbadis.2021.166294_bb0430", "volume": "7", "year": "2020" }, { "DOI": "10.1126/science.1085658", "article-title": "Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs", "author": "Anand", "doi-asserted-by": "crossref", "first-page": "1763", "journal-title": "Science", "key": "10.1016/j.bbadis.2021.166294_bb0435", "volume": "300", "year": "2003" }, { "DOI": "10.1016/j.jtbi.2008.07.030", "article-title": "Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors", "author": "Nukoolkarn", "doi-asserted-by": "crossref", "first-page": "861", "journal-title": "J. Theor. Biol.", "key": "10.1016/j.bbadis.2021.166294_bb0440", "volume": "254", "year": "2008" }, { "DOI": "10.1080/1061186X.2020.1853736", "article-title": "Potential inhibitors of SARS-CoV-2: recent advances", "author": "Jamalipour Soufi", "doi-asserted-by": "crossref", "first-page": "349", "journal-title": "J. Drug Target.", "key": "10.1016/j.bbadis.2021.166294_bb0445", "volume": "29", "year": "2020" }, { "DOI": "10.3390/v13060989", "article-title": "Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon", "author": "Samaha", "doi-asserted-by": "crossref", "first-page": "989", "journal-title": "Viruses", "key": "10.1016/j.bbadis.2021.166294_bb0450", "volume": "13", "year": "2021" }, { "DOI": "10.1016/S1473-3099(20)30883-5", "article-title": "Ct values and infectivity of SARS-CoV-2 on surfaces", "author": "Kampf", "doi-asserted-by": "crossref", "journal-title": "Lancet Infect. Dis.", "key": "10.1016/j.bbadis.2021.166294_bb0455", "volume": "21", "year": "2021" }, { "DOI": "10.1097/MJT.0000000000001377", "article-title": "Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19", "author": "Kory", "doi-asserted-by": "crossref", "first-page": "e299", "journal-title": "Am. J. Ther.", "key": "10.1016/j.bbadis.2021.166294_bb0460", "volume": "28", "year": "2021" }, { "author": "Elgazzar", "key": "10.1016/j.bbadis.2021.166294_bb0465", "series-title": "Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic", "year": "2020" }, { "DOI": "10.31546/2633-8653.1007", "article-title": "Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel", "author": "Héctor", "doi-asserted-by": "crossref", "journal-title": "J. Biomed. Res. Clin. Investig.", "key": "10.1016/j.bbadis.2021.166294_bb0470", "volume": "2", "year": "2020" }, { "DOI": "10.1371/journal.pone.0242184", "article-title": "Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients", "author": "Camprubí", "doi-asserted-by": "crossref", "journal-title": "PLOS ONE", "key": "10.1016/j.bbadis.2021.166294_bb0475", "volume": "15", "year": "2020" }, { "DOI": "10.1016/j.eclinm.2021.100959", "article-title": "Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial", "author": "Krolewiecki", "doi-asserted-by": "crossref", "journal-title": "EClinicalMedicine", "key": "10.1016/j.bbadis.2021.166294_bb0480", "volume": "37", "year": "2021" }, { "DOI": "10.1001/jama.2021.3071", "article-title": "Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19", "author": "López-Medina", "doi-asserted-by": "crossref", "first-page": "1426", "journal-title": "JAMA", "key": "10.1016/j.bbadis.2021.166294_bb0485", "volume": "325", "year": "2021" }, { "DOI": "10.1016/j.eclinm.2021.100744", "article-title": "Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?", "author": "Ramírez", "doi-asserted-by": "crossref", "journal-title": "EClinicalMedicine", "key": "10.1016/j.bbadis.2021.166294_bb0490", "volume": "32", "year": "2021" }, { "DOI": "10.1002/cpt.1889", "article-title": "The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19", "author": "Schmith", "doi-asserted-by": "crossref", "first-page": "762", "journal-title": "Clin. Pharmacol. Ther.", "key": "10.1016/j.bbadis.2021.166294_bb0495", "volume": "108", "year": "2020" } ], "reference-count": 97, "references-count": 97, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0925443921002271" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "1868" }